London: Britain's GSK has ⁠agreed to buy RAPT Therapeutics for USD 2.2 billion, accessing the U.S. biotech's experimental ...

By Pushkala Aripaka Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the ...

LONDON -Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer ...

GSK’s London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated ...

The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.

By Andrew MacAskill, Maggie Fick and Bhanvi Satija LONDON, Jan 26 (Reuters) - UK-based drugmakers AstraZeneca and GSK will ...

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion ...

GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults ...

A trio of drugmakers are treading the boards to raise awareness of global antimicrobial resistance (AMR). Pfizer, GSK and Shionogi have all signed on to sponsor the upcoming London run of the stage ...